Research ExplorerPublicationsLiver transplantation for hepatocellular carcinoma and cirrh...

Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels

Standard

Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels : is an expansion of the listing criteria justified? / Sotiropoulos, Georgios C; Malagó, Massimo; Bockhorn, Maximilian; Schmitz, Klaus J; Radtke, Arnold; Molmenti, Ernesto P; Schaffer, Randolph; Beckebaum, Susanne; Cicinnati, Vito R; Fouzas, Ioannis; Broelsch, Christoph E; Lang, Hauke.

In: HEPATO-GASTROENTEROL, Vol. 55, No. 86-87, 2008, p. 1671-7.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sotiropoulos, GC, Malagó, M, Bockhorn, M, Schmitz, KJ, Radtke, A, Molmenti, EP, Schaffer, R, Beckebaum, S, Cicinnati, VR, Fouzas, I, Broelsch, CE & Lang, H 2008, 'Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified?', HEPATO-GASTROENTEROL, vol. 55, no. 86-87, pp. 1671-7.

APA

Sotiropoulos, G. C., Malagó, M., Bockhorn, M., Schmitz, K. J., Radtke, A., Molmenti, E. P., Schaffer, R., Beckebaum, S., Cicinnati, V. R., Fouzas, I., Broelsch, C. E., & Lang, H. (2008). Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified? HEPATO-GASTROENTEROL, 55(86-87), 1671-7.

Vancouver

Sotiropoulos GC, Malagó M, Bockhorn M, Schmitz KJ, Radtke A, Molmenti EP et al. Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified? HEPATO-GASTROENTEROL. 2008;55(86-87):1671-7.

Bibtex

@article{142ea91a19274545ae0da08e3ff4b772,
title = "Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified?",
abstract = "BACKGROUND: Liver transplantation (LT) is the optimal therapy for hepatocellular carcinoma (HCC) in the setting of cirrhosis. The purpose of this study was to evaluate the results after LT for HCC patients with very low alpha fetoprotein (AFP) values both in our series and in literature reports.METHODOLOGY: Data obtained prospectively on 51 transplanted patients with HCC having AFP values < 30 ng/mL preoperatively were analyzed.RESULTS: Four-year overall and recurrence-free survival was 81% and 79%, respectively (median follow up of 35 months). Twenty nine patients (57%) were within the Milan criteria. Thirteen patients (25%) demonstrated advanced tumor stages. Ablative bridging treatments were attempted in 27 instances, and were associated with significantly worse overall and recurrence-free survivals (p=0.0209 and p=0.0111, respectively). Patients with AFP values < 30 ng/mL and no bridging treatments experienced 4-year overall and recurrence-free survivals of 96% and 95%, respectively.CONCLUSIONS: HCC patients with AFP values < 30 ng/mL who undergo LT with no bridging treatments experience excellent overall and recurrence-free survival rates, even with advanced tumor stages, independent of the Milan listing criteria.",
keywords = "Adult, Carcinoma, Hepatocellular, Female, Humans, Liver Cirrhosis, Liver Neoplasms, Liver Transplantation, Male, Middle Aged, Neoplasm Recurrence, Local, alpha-Fetoproteins",
author = "Sotiropoulos, {Georgios C} and Massimo Malag{\'o} and Maximilian Bockhorn and Schmitz, {Klaus J} and Arnold Radtke and Molmenti, {Ernesto P} and Randolph Schaffer and Susanne Beckebaum and Cicinnati, {Vito R} and Ioannis Fouzas and Broelsch, {Christoph E} and Hauke Lang",
year = "2008",
language = "English",
volume = "55",
pages = "1671--7",
number = "86-87",

}

RIS

TY - JOUR

T1 - Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels

T2 - is an expansion of the listing criteria justified?

AU - Sotiropoulos, Georgios C

AU - Malagó, Massimo

AU - Bockhorn, Maximilian

AU - Schmitz, Klaus J

AU - Radtke, Arnold

AU - Molmenti, Ernesto P

AU - Schaffer, Randolph

AU - Beckebaum, Susanne

AU - Cicinnati, Vito R

AU - Fouzas, Ioannis

AU - Broelsch, Christoph E

AU - Lang, Hauke

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Liver transplantation (LT) is the optimal therapy for hepatocellular carcinoma (HCC) in the setting of cirrhosis. The purpose of this study was to evaluate the results after LT for HCC patients with very low alpha fetoprotein (AFP) values both in our series and in literature reports.METHODOLOGY: Data obtained prospectively on 51 transplanted patients with HCC having AFP values < 30 ng/mL preoperatively were analyzed.RESULTS: Four-year overall and recurrence-free survival was 81% and 79%, respectively (median follow up of 35 months). Twenty nine patients (57%) were within the Milan criteria. Thirteen patients (25%) demonstrated advanced tumor stages. Ablative bridging treatments were attempted in 27 instances, and were associated with significantly worse overall and recurrence-free survivals (p=0.0209 and p=0.0111, respectively). Patients with AFP values < 30 ng/mL and no bridging treatments experienced 4-year overall and recurrence-free survivals of 96% and 95%, respectively.CONCLUSIONS: HCC patients with AFP values < 30 ng/mL who undergo LT with no bridging treatments experience excellent overall and recurrence-free survival rates, even with advanced tumor stages, independent of the Milan listing criteria.

AB - BACKGROUND: Liver transplantation (LT) is the optimal therapy for hepatocellular carcinoma (HCC) in the setting of cirrhosis. The purpose of this study was to evaluate the results after LT for HCC patients with very low alpha fetoprotein (AFP) values both in our series and in literature reports.METHODOLOGY: Data obtained prospectively on 51 transplanted patients with HCC having AFP values < 30 ng/mL preoperatively were analyzed.RESULTS: Four-year overall and recurrence-free survival was 81% and 79%, respectively (median follow up of 35 months). Twenty nine patients (57%) were within the Milan criteria. Thirteen patients (25%) demonstrated advanced tumor stages. Ablative bridging treatments were attempted in 27 instances, and were associated with significantly worse overall and recurrence-free survivals (p=0.0209 and p=0.0111, respectively). Patients with AFP values < 30 ng/mL and no bridging treatments experienced 4-year overall and recurrence-free survivals of 96% and 95%, respectively.CONCLUSIONS: HCC patients with AFP values < 30 ng/mL who undergo LT with no bridging treatments experience excellent overall and recurrence-free survival rates, even with advanced tumor stages, independent of the Milan listing criteria.

KW - Adult

KW - Carcinoma, Hepatocellular

KW - Female

KW - Humans

KW - Liver Cirrhosis

KW - Liver Neoplasms

KW - Liver Transplantation

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - alpha-Fetoproteins

M3 - SCORING: Journal article

C2 - 19102367

VL - 55

SP - 1671

EP - 1677

IS - 86-87

ER -